Advertisement

Pharmaceutical Medicine

, Volume 28, Issue 5, pp 265–271 | Cite as

Drug Development in Schizophrenia: Summary and Table

Adis Profile Summary

Older conventional antipsychotics (APs) have given way to newer atypical APs, but many patients remain refractory to treatment. Genetic and biomarkers studies have revealed that schizophrenia is a very heterogeneous disease. Current unmet needs include lack of adequate efficacy—incomplete suppression of psychosis prevents brain repair leading to permanent cognitive deficits—novel agents with lower neurotoxicity and vascular risk, and a need for earlier diagnosis of the negative symptoms preceding psychosis and thus earlier treatment to prevent irreversible effects.

Active research areas include prodromal diagnosis and treatment, and genotyping and development of biomarkers to predict psychosis and response to treatment. Regarding treatment development, recent research focuses on combination antipsychotics, adjunctive therapies to improve efficacy and mitigate tolerability issues, and many novel antipsychotic classes with innovative mechanisms of action (MOA). Overall, the drug...

Copyright information

© Springer International Publishing Switzerland 2014

Personalised recommendations